Future perspectives

It is clear that leukemia in DS follows an independent genetic trajectory compared to leukemia in non-DS patients. Identifying and confirming the altered genetic pathway will improve diagnosis and enhance treatment strategies. Large-scale population studies are required for establishing appropriate treatment strategies and thus preventing undue toxicities in patients.


Continue Reading

References
1. Xavier A.C., Ge Y., Taub J.W. Down Syndrome and Malignancies: A Unique ClinicalRelationship. J Mol Diagn. 2009;11(5):371–80.

2. Rabin K.R., Whitlock J.A. Malignancy in Children with Trisomy 21. Oncologist. 2009;14(2):164–73.

3. Forestier E., Izraeli S., Beverloo B., et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;111:1575–83.

4. Hertzberg L., Vendramini E., Ganmore I., et al. Down syndrome acute lymphoblastic leukemia, a highly heterogenous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010;115:1006–17.

5. Mullighan C.G., Collins-Underwood J.R., Phillips L.A.A., et al. Rearrangement of CRLF2 in B-progenitor and Down syndrome associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243–46.

6. Malinge S., Izraeli S., Crispino J.D. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood. 2009;113:2619–28.

7. Kanegane H., Watanabe S., Nomura K., Xu G., Ito E., Miyawaki T. Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome. Int J Hematol. 2007;86(3):250–2.

8. Key player found for a cancer typical in Down syndrome [news release]. Children’s Hospital Boston; March 1, 2010. http://www.eurekalert.org/pub_releases/2010-03/chb-kpf030110.php. Accessed May 20, 2012.

9. Maloney K.W., Carroll W.L., Carroll A.J., et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children’s Oncology Group. Blood. 2010;116:1045–50.

10. Loudin M..G, Wang J., Leung H.C.E., et al. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia. 2011;25:1555–63.

11. Yokoyama T., Toki T., Aoki Y., et al. Identification of TRIB1 R107L gain-of-function mutation in human acute megakaryocytic leukemia. Blood. 2012;119:2608–11.

12. Blink M., van den Heuvel-Eibrink M.M., de Haas V., et al. Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease. Haematologica. 2012;97(4):632–4.

13. New chromosomal abnormality identified in leukemia associated with Down syndrome [news release]. St. Jude Children’s Research Hospital; October 18, 2009. http://www.eurekalert.org/pub_releases/2009-10/sjcr-nca101509.php. Accessed May 20, 2012.

14. Ensor H.M., Schwab C., Russell L.J., et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood. 2011;117:2129–36.

15. Lundin C., Hjorth L., Behrendtz M., et al. High Frequency of BTG1 Deletions in Acute Lymphoblastic Leukemia in Children with Down Syndrome. Genes Chromosomes Cancer. 2012;51:196–206.

16. Sorrell A.D., Alonzo T.A., Hilden J.M., et al. Favorable survival maintained in children who have myeloid leukemia associated with down syndrome using reduced-dose chemotherapy on children’s oncology group trial A2971. Cancer. 2012;doi: 10.1002/cncr.27484.

17. Moritake H., Yamada A., Kimoto Y., et al. Acute megakaryoblastic leukemia and severe pulmonary fibrosis in a child with Down syndrome: Successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease. Am J Hematol. 2012;87(4)447–50.

18. Rabin K.R., Smith J., Kozinetz C. Myelosuppression and Infectious Complications in Children With Down Syndrome and Acute Lymphoblastic Leukemia. Pediatric Blood Cancer. 2012;58:633–35.

19. Reinhardt D., Reinhardt K., Neuhoff C., et al. GATA1-mutation associated leukemia in children with trisomy 21 mosaic. Klin Padiatr. 2012;224(3):153–5.